drugset

drugset / Trial / NCT01031225

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

NCT01031225 ↗

Phase 2 Completed 113 enrolled Synta Pharmaceuticals Corp.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).

Timeline

Start: 2009-11
Primary completion: 2013-07
Completion: 2014-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ganetespib	Small molecule	—	Intravenous

Indications